Welcome | Sign In
ECommerceTimes.com
News

Inktomi Falls on Profit Warning

Print Version
E-Mail Article
Reprints

Inktomi shares have taken a beating lately, and are trading near a 52-week low of 13.25.


Infusionsoft is offering a free, 15-day trial to small businesses looking to grow fast. With email marketing, automated follow-up, and CRM, Infusionsoft is the only marketing software guaranteed to double your sales. Sign up for a free trial today.

Inktomi Corp. (Nasdaq: INKT) was down 2.69 at 15.81 early Thursday after the company warned that revenue Grow Your Business-Fast! Sign up for a FREE trial of Infusionsoft and double your sales in 12 months. and earnings for the first quarter ended December 31st will be below previous expectations.

The Foster City, California-based maker of Internet software said revenue for the quarter will be US$80 million to $81 million, up 121 to 124 percent over last year's first quarter, with pro forma diluted earnings per share of breakeven to a penny.

For the fourth quarter, Inktomi reported revenue of $78.6 million, up 190 percent from a year earlier, and pro forma earnings before special items of $8.8 million, or 7 cents per share, compared with a loss of $6.1 million, or 6 cents.

President and chief executive officer David Peterschmidt said the lower expectations for the fourth quarter reflect a sluggish economy. "The current conditions in the U.S. capital markets and the broader economy have resulted in a slowdown in infrastructure spending," Peterschmidt said in a statement issued after the close of trading Wednesday.

"While our business will be affected by macroeconomic conditions in the near term, we are confident in the long-term outlook for our infrastructure products and services," Peterschmidt added. "We believe we have the management, products and financial focus to foster long-term benefits for our shareholders and customers worldwide."

Inktomi shares have taken a beating lately, and are trading near a 52-week low of 13.25, well below the year's high of 241.50.

Thomas Weisel Partners reportedly downgraded Inktomi to market perform from strong buy following the latest announcement.

On Wednesday, Inktomi fell following reports that analysts at Merrill Lynch and Robertson Stephens downgraded the stock. Merrill's Henry Blodget reportedly lowered his intermediate-term rating to accumulate from buy, citing the effects of a slowdown in information technology spending.

Inktomi plans to report first-quarter results on January 18th.

Social Networking Toolbox:

Print Version E-Mail Article Reprints More by Nora Macaluso   RSS

Don't miss a story -- sign up for our FREE e-mail newsletters and view the latest headlines at a glance.
Tech News Flash [ View Sample ]
E-Commerce Minute [ View Sample ]
ECT News Network Weekly Newsletter [ View Sample ]
Shortcuts
ECT News Network Information
Reader Services
Corporate
ECT News Network